Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Hester Biosciences...

    Hester Biosciences appoints Sahil Shah as CFO, Dr Rahul Srivastava as Vice President

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-08T11:00:16+05:30  |  Updated On 8 March 2020 11:00 AM IST
    Hester Biosciences appoints Sahil Shah as CFO, Dr Rahul Srivastava as Vice President

    Ahemdabad: Through a recent announcement Haster Biosciences has stated that Mr Sahil Shah has been appointed as CFO of Hester Biosciences with effect from 1 March 2020. Having graduated with a bachelor's in commerce in 2011 from Gujarat University, Sahil joined Hester in July 2015. Since then, he has been directly involved in accounts and finance functions. His strong financial instincts enabled him to implement internal finance controls at Hester. He has capabilities towards financial planning and accounting strategies as well as is a good communicator. Currently, Sahil is pursuing his final group in Chartered Accountancy.

    Being with Hester for a little under 5 years already, Sahil is familiar with Hester's culture and philosophy. This is a very big advantage for Hester as well as for him while taking over the responsibilities as a CFO.

    The Business Development Division has been set-up to focus on market research, to see the needs of the market and develop strategies towards achieving sustainable sales growth. The division would support the sales and marketing divisions with well-defined qualitative and quantitative objectives.

    Read also: Hester Biosciences Q4 net up 27 percent

    Besides, Dr Rahul Srivastava has been appointed as Vice President – Business Development, at Hester Biosciences, with immediate effect. Rahul has been with Hester since Feb 2018, earlier heading the Veterinary Social Business Division at Hester. His work experience is vast, encompassing working in the private sector with corporates, in government institutes as well as in an international NGO. Academically, he has earned a Master of Veterinary Medicine (MVSc- Medicine) from The Indian Veterinary Research Institute and has done his MBA in Agribusiness.

    These changes have been made keeping short-term and long-term organisational objectives as paramount.

    Hester Biosciences Limited is one of India's animal healthcare companies and the second-largest poultry vaccine manufacturer. Mr Rajiv Gandhi, a first-generation entrepreneur founded Hester in 1987 and successfully transformed a small proprietary trading business into Asia's largest single-location animal biological manufacturing facility. The Company's key strength is embedded in its cutting-edge research and development capabilities.

    Read also: Bill Gates acknowledges Hester for developing a Newcastle Disease Vaccine

    sahil-shahhester-biosciencesdr-rahul-srivastava

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok